Baxter International's latest quarterly filing reveals sales growth supported by strong demand for its intravenous (IV) solutions and infusion systems, partially offset by margin contraction due to product recalls and inflationary cost pressures. The company's voluntary recall of its Novum IQ large volume pump (LVP) has disrupted sales in that product line, with remediation estimated at $105 million during 2025. Baxter continues investing in capital expenditures focused on expanding manufacturing capacity and improving quality systems to support future growth. Industry-wide supply chain constraints and currency fluctuations pose ongoing risks, while the company's broad product portfolio and regulatory approvals support a defensible competitive position. Monitoring recall remediation progress and supply chain recovery will be critical near-term performance drivers.